SURGICAL INNOVATIONS GROUP PLC

Earnings Release • Jan 13, 2020

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 5067Z

Surgical Innovations Group PLC

13 January 2020

Surgical Innovations Group Plc

(the "Group")

Year-end Trading Update

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of innovative technology for minimally invasive surgery, provides an update on trading for the year ended 31 December 2019.

Sales for the second half of the year were approximately 10% higher than the first half, resulting in revenue for the full year of approximately £10.7m. Gross margin was within target range and the resulting adjusted profit before tax is anticipated to be in line with market expectations.

In the final quarter of 2019, the Group concluded agreements to extend important contractual relationships including the exclusive manufacture of the Fix-8 device for Advanced Medical Solutions plc until June 2024, and the U.K. exclusive distribution of the Dexter robot for Distalmotion SA until October 2022.

The Group continued to be cash generative and the Board has elected to repay £1.0m of term loan in advance of the due date from available cash resources. The closing net cash balances of the Group stood at approximately £0.5m at the year end.

Audited results for the year ended 31 December 2019 will be released in late March 2020.

For further information contact:

Surgical Innovations Group Plc	www.sigroupplc.com
David Marsh, CEO	Tel: +44 (0)113 230 7597
Charmaine Day, Co Sec & GFC
Walbrook PR (Financial PR & Investor Relations)	Tel: +44 (0)20 7933 8780 or si@walbrookpr.com
Paul McManus / Lianne Cawthorne	Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303
N+1 Singer (Nominated Adviser and Broker)	+44 (0)20 7496 3000
Richard Lindley / Rachel Hayes

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

UPDFLFLDLIIILII